1-(2-氟苯基)哌嗪 | 1011-15-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-氟苯基)哌嗪
• 中文别名: 1-2-氟苯基哌嗪
• 英文名称: 1-(o-fluorophenyl)piperazine
• 英文别名: 1-(2-fluorophenyl)piperazine
• CAS: 1011-15-0
• 化学式: C₁₀H₁₃FN₂
• mdl: MFCD00040726
• 分子量: 180.225
• InChiKey: IVTZRJKKXSKXKO-UHFFFAOYSA-N

物化性质

• 熔点：
  44-48℃
• 沸点：
  150 °C/3 mmHg (lit.)
• 密度：
  1.141 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）
• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 安全说明：
  S24/25,S26,S36
• 危险品运输编号：
  UN 2923
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 包装等级：
  II
• 危险标志：
  GHS07
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338
• 储存条件：
  请将容器密封保存，并存放在阴凉、干燥处。

SDS

Name:	1-(2-Fluorophenyl)piperazine 97%(GC) Material Safety Data Sheet
Synonym:	None listed
CAS:	1011-15-0

Section 1 - Chemical Product MSDS Name:1-(2-Fluorophenyl)piperazine 97%(GC) Material Safety Data Sheet
Synonym:None listed

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1011-15-0	1-(2-Fluorophenyl)piperazine	97	213-780-4

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1011-15-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: white to pale yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 150 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: 109 deg C ( 228.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: 1.141 g/cm3
Molecular Formula: C10H13FN2
Molecular Weight: 180.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1011-15-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Fluorophenyl)piperazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1011-15-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1011-15-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1011-15-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于合成神经活性化合物的中间体。

反应信息

• 作为反应物：
  描述：

  1-(2-氟苯基)哌嗪 在 potassium hydroxide 、 sodium hydroxide 作用下， 以 二甲基亚砜 、 丙酮 为溶剂， 反应 31.5h， 生成 1-{3-[4-(2-fluorophenyl) piperazin-1-yl] propyl}-1H-indole
  参考文献：
  名称：

  钯催化芳基腈的定向碳-碳键活化用于氰基转移

  摘要：

  在此，我们报道了使用芳基腈作为氰基源，通过钯催化的定向 C-CN 活化反应进行吲哚的 C-H 氰化。苯氧基取向基团的使用是C-CN键断裂的关键。该方案具有底物范围广、效率高、区域选择性高的特点。此外，该方案的实际应用在吲哚衍生物的后期功能化和合成中得到了展示，吲哚衍生物是通过氰化过程衍生自药物和天然产物。

  DOI：

  10.1021/acs.orglett.4c00429
• 作为产物：
  描述：

  tert-butyl 4-(2-fluorophenyl)piperazine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(2-氟苯基)哌嗪
  参考文献：
  名称：

  新型GLUT抑制剂的鉴定

  摘要：

  使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1（GLUT1）的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究（SAR），揭示了必要的结构动机（即，邻甲氧基取代的苯，哌嗪和嘧啶）。对GLUT2的选择性非常好，并且最初的体外和体内药代动力学（PK）研究令人鼓舞。

  DOI：

  10.1016/j.bmcl.2016.02.050
• 作为试剂：
  描述：

  2-(氯甲基)-1H-噻吩并[3,4-d]咪唑 在 1-(2-氟苯基)哌嗪 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 生成 2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole
  参考文献：
  名称：

  [EN] FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  [FR] COMPOSES AROMATIQUES BICYCLIQUES CONDENSES UTILES DANS LE TRAITEMENT DE DYSFONCTIONNEMENT SEXUEL

  摘要：

  本发明涉及使用化合物(I)的治疗性功能障碍，并涉及含有化合物(I)的组合物用于治疗性功能障碍。

  公开号：

  WO2003101994A1

文献信息

• [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
  申请人：GRUENENTHAL GMBH

  公开号：WO2010099938A1

  公开（公告）日：2010-09-10

  The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。
• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• [EN] NOVEL TETRAHYDROQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS INÉDITS DE LA TÉTRAHYDROQUINOLINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012101068A1

  公开（公告）日：2012-08-02

  A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1 to R8, A1 to A3 have the significance given in claim 1, can be used as AMPK modulators for treating obesity, hyperglycemia or type 2 diabetes.

  化合物的化学式（I）或其药用可接受的盐或酯，其中R1至R8，A1至A3具有权利要求1中给定的含义，可用作AMPK调节剂，用于治疗肥胖症、高血糖或2型糖尿病。
• Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing
  作者：Zhonghua Li、Tingting Qin、Zhongrui Li、Xuan Zhao、Xinhui Zhang、Taoqian Zhao、Nian Yang、Jinxin Miao、Jinlian Ma、Zhenqiang Zhang

  DOI：10.1016/j.ejmech.2021.113778

  日期：2021.12

  remarkable capacity to inhibit colony formation, suppress migration and induce apoptosis of MGC803 cells. Furthermore, in MGC-803 xenograft mouse model, 5k treatment resulted in significant reduction in tumor size by 81.6% and 96.1% at dosages of 40 and 80 mg/kg/d, respectively. Our findings indicate that erlotinib-based analogs provide a novel structural set of LSD1 inhibitors with potential for further

  组蛋白赖氨酸特异性去甲基化酶 1 (LSD1) 是一种重要的表观遗传调节剂，并以不同的方式参与恶性转化和肿瘤发病机制。因此，LSD1的抑制为癌症治疗提供了一个有吸引力的治疗靶点。基于药物再利用策略，我们筛选了我们内部针对 LSD1 的化学库，发现 EGFR 抑制剂厄洛替尼（一种 FDA 批准的肺癌药物）对 LSD1 的效力较低（IC 50  = 35.80 μM）。在此，我们报告了我们进一步的药物化学努力，以获得高度水溶性的厄洛替尼类似物5k (>100 mg/mL)，其对 LSD1 的抑制活性显着增强 (IC 50  = 0.69 μM) 以及更高的特异性。在 MGC-803 细胞中，5k抑制 LSD1 的去甲基化，表明其对酶的细胞活性。此外，5k具有显着的抑制集落形成、抑制迁移和诱导MGC803细胞凋亡的能力。此外，在 MGC-803 异种移植小鼠模型中，5k治疗导致肿瘤大小分别在 40

表征谱图